IN-119873 / Korea Kolmar - LARVOL DELTA

IN-119873, the next-generation allosteric EGFR TKI, a potent and highly selective EGFR L858R for the treatment of osimertinib-resistant NSCLC (AACR 2024) - "IN-119873 also demonstrated favorable blood-brain-barrier penetration with promising intracranial efficacy in the H1975-luc brain metastasis model both mono or in combination with osimertinib. As a selective, orally available, and CNS-penetrable next-generation allosteric EGFR-TKI, IN-119873 is currently undergoing IND-enabling studies and has the potential to demonstrate activity in both first-line and resistance settings, either as a monotherapy or in combination with 3rd generation EGFR TKI."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HK inno.N to present NSCLC drug candidate at AACR cancer meet in US (Korea Biomedical Review) - "HK inno.N said it plans to present the interim preclinical research findings on IN-119873, its next-generation allosteric EGFR-tyrosine kinase inhibitor (EGFR-TKI) candidate, targeting non-small cell lung cancer (NSCLC) patients with the L858R genetic mutation, during the upcoming annual meeting of the American Association for Cancer Research (AACR) in April."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor